抄録
We investigated whether UGT1A1 polymorphisms are associated with the prognosis of ovarian cancer patients treated with irinotecan. UGT1A1 genotypes were analyzed in 11 stage I ovarian clear cell carcinoma patients who received irinotecan as first-line therapy. Progression-free survival, overall survival and adverse events were also assessed for each genotype. Three patients harbored UGT1A1*1/*6 while another three harbored UGT1A1*1/*28. Two patients with a wildtype genotype experienced recurrence and one died, whereas no recurrence or death was observed in patients with heterozygous genotypes. Adverse events tended to be more severe in patients with UGT1A1*6 and *28, although progression-free survival and overall survival rates tended to be better than in wild-type; the differences were not significant. We conclude that UGT1A1 polymorphisms have the potential to be a prognostic marker of irinotecan treatment.
| 本文言語 | 英語 |
|---|---|
| ページ(範囲) | 170-174 |
| ページ数 | 5 |
| ジャーナル | Japanese journal of clinical oncology |
| 巻 | 47 |
| 号 | 2 |
| DOI | |
| 出版ステータス | 出版済み - 01-02-2017 |
| 外部発表 | はい |
UN SDG
この成果は、次の持続可能な開発目標に貢献しています
-
SDG 3 すべての人に健康と福祉を
All Science Journal Classification (ASJC) codes
- 腫瘍学
- 放射線学、核医学およびイメージング
- 癌研究
フィンガープリント
「UGT1A1 polymorphism as a prognostic indicator of stage I ovarian clear cell carcinoma patients treated with irinotecan」の研究トピックを掘り下げます。これらがまとまってユニークなフィンガープリントを構成します。引用スタイル
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver